Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
Résultats de la recherche
Tout
Rechercher les filtres
-
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the...
-
On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
-
OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham...
-
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that...
-
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous...
-
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase...
-
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod)...
-
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its...
-
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant...
-
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...